clinical trials

Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial
Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial
Pharmaceutical Business Review
Inovio
FDA
COVID-19
vaccines
clinical trials
Flag link:
Moderna's COVID-19 vaccine aces phase 3, with no severe cases
Moderna's COVID-19 vaccine aces phase 3, with no severe cases
Fierce Biotech
Moderna Therapeutics
vaccines
clinical trials
COVID-19
Flag link:
J&J, erring on caution, tests new 2-dose regimen for COVID-19 vaccine
J&J, erring on caution, tests new 2-dose regimen for COVID-19 vaccine
Fierce Biotech
JNJ
COVID-19
vaccines
clinical trials
Flag link:
Inovio Jumps on Progress of Coronavirus Vaccine Candidate
Inovio Jumps on Progress of Coronavirus Vaccine Candidate
TheStreet.com
Inovio
vaccines
clinical trials
COVID-19
Flag link:
J&J taps into BARDA well a third time to speed up its PhIII Covid-19 vaccine trial
J&J taps into BARDA well a third time to speed up its PhIII Covid-19 vaccine trial
Endpoints
JNJ
BARDA
COVID-19
vaccines
clinical trials
Flag link:
Gilead and Novo plot next steps after trial data from NASH combo
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
Flag link:
Shortage of monkeys slowed down Eli Lilly's Covid-19 antibody partner. And it's a problem for everyone
Shortage of monkeys slowed down Eli Lilly's Covid-19 antibody partner. And it's a problem for everyone
Endpoints
COVID-19
animal studies
clinical trials
antibodies
Eli Lilly
Shanghai Junshi Biosciences
Flag link:
Pfizer says placebo patients will eventually get its Covid-19 vaccine. The question of when is complicated
Pfizer says placebo patients will eventually get its Covid-19 vaccine. The question of when is complicated
Stat
clinical trials
Pfizer
placebo
vaccines
COVID-19
Flag link:
AstraZeneca cancer drug found ineffective for COVID-19
AstraZeneca cancer drug found ineffective for COVID-19
BioPharma Dive
AstraZeneca
Calquence
clinical trials
COVID-19
Flag link:
Woodcock: Pharma, regulators have lessons to learn from COVID
Woodcock: Pharma, regulators have lessons to learn from COVID
RAPS.org
Janet Woodcock
pandemic
COVID-19
clinical trials
Emergency Use Authorization
Flag link:
Tapping GSK tech, Medicago kickstarts later-stage COVID vax tests
Tapping GSK tech, Medicago kickstarts later-stage COVID vax tests
Fierce Biotech
GSK
Medicago
clinical trials
vaccines
COVID-19
Flag link:
Moderna says it's reached the required number of Covid-19 cases for its first interim analysis. When is the readout coming?
Moderna says it's reached the required number of Covid-19 cases for its first interim analysis. When is the readout coming?
Endpoints
Moderna Therapeutics
COVID-19
vaccines
clinical trials
Flag link:
ImmunityBio, NantKwest announce positive interim phase 1 safety data of hAd5 Covid-19 vaccine dose study
ImmunityBio, NantKwest announce positive interim phase 1 safety data of hAd5 Covid-19 vaccine dose study
Pharmaceutical Business Review
ImmunityBio
NantKwest
clinical trials
COVID-19
vaccines
Flag link:
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Endpoints
Pfizer
JAK inhibitors
abrocitinib
Dupixent
atopic dermatitis
clinical trials
Flag link:
Novel vaccines typically take 8 years of clinical development: Study
Novel vaccines typically take 8 years of clinical development: Study
RAPS.org
FDA
clinical trials
drug development
vaccines
COVID-19
Flag link:
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
Flag link:
CureVac climbs on vaccine data despite tolerability questions
CureVac climbs on vaccine data despite tolerability questions
Fierce Biotech
CureVac
vaccines
clinical trials
Flag link:
Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
Endpoints
Locus Biosciences
CARB-X
CRISPR
rUTIs
UTIs
bacteriophage
EIP Pharma
Vertex Pharmaceuticals
dementia
clinical trials
Flag link:
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Flag link:
Amgen, AstraZeneca's tezepelumab hits goal in asthma phase 3
Amgen, AstraZeneca's tezepelumab hits goal in asthma phase 3
Fierce Pharma
Amgen
AstraZeneca
tezepelumab
asthma
severe asthma
clinical trials
Flag link:

Pages